BMO Capital Downgrades Ionis Pharmaceuticals to Market Perform, Lowers Price Target to $60
Portfolio Pulse from Benzinga Newsdesk
BMO Capital has downgraded Ionis Pharmaceuticals from Outperform to Market Perform and lowered its price target from $67 to $60.
August 02, 2024 | 9:15 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
BMO Capital has downgraded Ionis Pharmaceuticals from Outperform to Market Perform and lowered its price target from $67 to $60.
The downgrade from Outperform to Market Perform and the reduction in the price target from $67 to $60 by BMO Capital is likely to negatively impact Ionis Pharmaceuticals' stock price in the short term as it reflects a less optimistic outlook from a reputable analyst.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100